Literature DB >> 24737444

Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure.

Catriona Shaw1, Roslyn J Simms2, David Pitcher1, Richard Sandford3.   

Abstract

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the leading genetic cause of end-stage renal failure (ESRF). The epidemiology of the incident ADPKD patient cohort requiring renal replacement therapy (RRT) in England and Wales has not been described.
METHODS: We used a retrospective cohort design. Incident adult patients commencing RRT between 1 January 2000 and 31 December 2011 in England and Wales were identified from the UK Renal Registry. Patients were stratified into three groups based on primary renal diagnosis (PRD): (i) ADPKD, (ii) diabetes as PRD, (iii) individuals with another PRD ('other'). Baseline demographics, comorbidity, care-related measures and outcomes including patient survival are described.
RESULTS: A total of 52,608 individuals started RRT during the study period, 3598 (6.8%) had ADPKD, 12,137 (23.1%) diabetes as PRD and 36,873 had another PRD diagnosis. The median age of commencing RRT was 55 years in the ADPKD group compared with 62 and 66 years in those with diabetes or 'other' PRD, respectively. The median age of starting RRT did not change within the ADPKD group over the 10-year period. Median age at death was similar across all groups. The ADPKD group had a lower hazard for all-cause mortality compared with the 'other' PRD group (adjusted hazard ratio 0.45, 95% CI 0.38-0.53). In all PRD groups, crude mortality rates had improved between 2000-06 and 2007-11.
CONCLUSION: Although engaged in renal services earlier than some other patient groups, individuals with ADPKD start RRT at a younger age and this has remained unchanged over the last decade. Developing a nationwide cohort and an enhanced disease-specific dataset would facilitate a wide range of research and quality improvement initiatives to try to modify progression to ESRF and the course of RRT. © Crown copyright 2014.

Entities:  

Keywords:  ADPKD; end-stage kidney disease; epidemiology and outcomes; renal replacement therapy

Mesh:

Year:  2014        PMID: 24737444     DOI: 10.1093/ndt/gfu087

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  20 in total

1.  The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Emilie Cornec-Le Gall; Marie-Pierre Audrézet; Annick Rousseau; Maryvonne Hourmant; Eric Renaudineau; Christophe Charasse; Marie-Pascale Morin; Marie-Christine Moal; Jacques Dantal; Bassem Wehbe; Régine Perrichot; Thierry Frouget; Cécile Vigneau; Jérôme Potier; Philippe Jousset; Marie-Paule Guillodo; Pascale Siohan; Nazim Terki; Théophile Sawadogo; Didier Legrand; Victorio Menoyo-Calonge; Seddik Benarbia; Dominique Besnier; Hélène Longuet; Claude Férec; Yannick Le Meur
Journal:  J Am Soc Nephrol       Date:  2015-07-06       Impact factor: 10.121

2.  Analysis of mutations in six Chinese families with autosomal dominant polycystic kidney disease.

Authors:  Hanlu Wang; Sen Dai; Jianhui Zhang; Yi Li; Yumian Gan; Tao Lu; Yaobin Zhu; Jiabin Wu; Ning Lin; Faqiang Tang; Jiewei Luo
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

Review 3.  Polycystic kidney disease.

Authors:  Carsten Bergmann; Lisa M Guay-Woodford; Peter C Harris; Shigeo Horie; Dorien J M Peters; Vicente E Torres
Journal:  Nat Rev Dis Primers       Date:  2018-12-06       Impact factor: 52.329

4.  Biliary Tract and Liver Complications in Polycystic Kidney Disease.

Authors:  Parminder K Judge; Charlie H S Harper; Benjamin C Storey; Richard Haynes; Martin J Wilcock; Natalie Staplin; Raph Goldacre; Colin Baigent; Jane Collier; Michael Goldacre; Martin J Landray; Christopher G Winearls; William G Herrington
Journal:  J Am Soc Nephrol       Date:  2017-05-02       Impact factor: 10.121

5.  Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.

Authors:  Godela M Brosnahan; Kaleab Z Abebe; Frederic F Rahbari-Oskoui; Charity G Patterson; Kyongtae T Bae; Robert W Schrier; William E Braun; Arlene B Chapman; Michael F Flessner; Peter C Harris; Ronald D Perrone; Theodore I Steinman; Vicente E Torres
Journal:  Curr Hypertens Rev       Date:  2017

6.  Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States.

Authors:  Rita L McGill; Milda R Saunders; Alexandra L Hayward; Arlene B Chapman
Journal:  Clin J Am Soc Nephrol       Date:  2022-06-20       Impact factor: 10.614

7.  Polycystic kidney disease: Progression of polycystic kidney disease--a lack of progress?

Authors:  Stephen McDonald; Gopala Rangan
Journal:  Nat Rev Nephrol       Date:  2014-08-05       Impact factor: 28.314

8.  Genomics in the renal clinic - translating nephrogenetics for clinical practice.

Authors:  Andrew Mallett; Christopher Corney; Hugh McCarthy; Stephen I Alexander; Helen Healy
Journal:  Hum Genomics       Date:  2015-06-24       Impact factor: 4.639

Review 9.  A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease.

Authors:  Claire Woon; Ashleigh Bielinski-Bradbury; Karl O'Reilly; Paul Robinson
Journal:  BMC Nephrol       Date:  2015-08-15       Impact factor: 2.388

10.  Primary prevention of cardiovascular disease events with renin-angiotensin system blockade in autosomal dominant polycystic kidney disease dialysis patients: A nationwide cohort study.

Authors:  Chien-Lin Lu; Chien-Yu Lin; Lian-Yu Lin; Pau-Chung Chen; Cai-Mei Zheng; Kuo-Cheng Lu; Dong-Feng Yeih
Journal:  Medicine (Baltimore)       Date:  2021-07-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.